Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.

Today, we return to Filament Health (FH.NEO), a Canadian-based psychedelics company focused on building its valuable IP portfolio regarding the natural extraction of psilocybin compounds for clinical grade therapeutic pharmaceuticals with optimum bioavailability.

Enjoy!